Paragon Therapeutics, Inc. And WuXi Biologics Entered Into A Biologics Master Services Agreement, Which Was Later Transferred To Aeglea Biotherapeutics, Inc., Governing Development Activities And Manufacturing For The Company's SPY001 Program
Portfolio Pulse from Benzinga Newsdesk
Paragon Therapeutics and WuXi Biologics have entered into a Biologics Master Services Agreement, which was later transferred to Aeglea Biotherapeutics. The agreement governs development activities and manufacturing for Paragon's SPY001 program.
September 25, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aeglea Biotherapeutics has taken over the Biologics Master Services Agreement between Paragon Therapeutics and WuXi Biologics for the SPY001 program.
The transfer of the Biologics Master Services Agreement to Aeglea Biotherapeutics indicates a significant role for the company in the development and manufacturing of the SPY001 program. This could potentially lead to increased revenues and profitability for Aeglea, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100